Comparable stake leader
Flying Fish Ventures L.P.
SEC ownership of Sofgen Pharma S.A.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001863362.
Disclosed value leader
Flying Fish Ventures L.P.
Comparable rows
5/10
Latest evidence
18 Mar 2026
- Public ticker
- PROCF, PRCWF on OTC
- Parsed ownership sources
- 13D/G and 3/4/5
- Largest SEC-reported holder
- Flying Fish Ventures L.P.
- Latest 13D/G holder
- Flying Fish Ventures L.P.
- Latest parsed ownership date
- 18 Mar 2026
- Issuer CIK
- 0001863362
- Issuer location
- Luxembourg
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Sofgen Pharma S.A. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Flying Fish Ventures L.P.
Disclosed value leader
Flying Fish Ventures L.P.
Comparable rows
5/10
Latest evidence
18 Mar 2026
13D/G
3/4/5
Lead comparable stake: 84%
5 rows are not safely comparable across share classes.
13D/G row: Flying Fish Ventures L.P.
Showing 1-8 of 10 holder rows.
Quick read
Flying Fish Ventures L.P. leads the comparable SEC ownership view at 84%.
5 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Flying Fish Ventures L.P.'s linked filing trail.
Comparable ownership
Top 5
Flying Fish Ventures L.P.
84%
Hoche Partners Pharma Holding S.A.
84%
Saint Thomas Commercial S.A.
84%
Becaril S.A.
53%
Chemo Project, S.A.
53%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Flying Fish Ventures L.P. |
13D/G
|
84%
|
$2,867,018,231
2,077,549,443 shares
|
$0 | 09 Apr 2025 |
| Hoche Partners Pharma Holding S.A. |
13D/G
|
84%
|
$2,867,018,231
2,077,549,443 shares
|
$0 | 16 Apr 2025 |
| Saint Thomas Commercial S.A. |
13D/G
|
84%
|
$2,867,018,231
2,077,549,443 shares
|
$0 | 09 Apr 2025 |
| Becaril S.A. |
13D/G
|
53%
|
$1,800,235,163
1,304,518,234 shares
|
$0 | 09 Apr 2025 |
| Chemo Project, S.A. |
13D/G
|
53%
|
$1,800,235,163
1,304,518,234 shares
|
$0 | 09 Apr 2025 |
| Alexandre Weinstein Manieu |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
—
626,495,816 shares
|
— | 18 Mar 2026 |
| Muniz Fernando Sebastian Moreira |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
—
305,309,149 shares
|
— | 18 Mar 2026 |
| Ruben Minski |
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
—
class O/S missing
|
—
31,338,454 shares
|
— | 29 Sep 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Sofgen Pharma S.A.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Jose Minski
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jose Minski | Director, 10%+ Owner | Mixed | 29 Sep 2021 | |||
| Ruben Minski | Chief Executive Officer, Director, 10%+ Owner | Mixed | 29 Sep 2021 | |||
| Deseja Trust | 10%+ Owner | Mixed | 29 Sep 2021 | |||
| Angelini Melissa Andreia Silva | Interim CEO | Mixed | 18 Mar 2026 | |||
| Camacho Carlos Romero | Director | Mixed | 18 Mar 2026 | |||
| Claro Manuel Jose Vial | Director | Mixed | 18 Mar 2026 | |||
| Muniz Fernando Sebastian Moreira | Director, 10%+ Owner | Mixed | 18 Mar 2026 | |||
| Jaramillo Daniel Augusto Bernal | Director | Mixed | 18 Mar 2026 | |||
| Iragorri Carlos Garcia | Director | Mixed | 18 Mar 2026 | |||
| Alberto Eguiguren | Director | Mixed | 18 Mar 2026 | |||
| Luis Alberto Palacios | Chief Commercial Officer | Mixed | 18 Mar 2026 | |||
| Alexandre Weinstein Manieu | Director, 10%+ Owner | Mixed | 18 Mar 2026 | |||
| Nicolas Alexandre Weinstein | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Sofgen Pharma S.A.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Muniz Fernando Sebastian Moreira | PROCF | Ordinary Shares | 0 | 305,309,149 | 18 Mar 2026 | By Becaril S.A. | ||||
| Alexandre Weinstein Manieu | Ordinary Shares | 0 | 626,495,816 | 18 Mar 2026 | By Hoche Partners Pharma Holdings LLC |
* marks a reported price that did not pass the local price check.